Sarepta’s Gene Therapy Elevidys Under Scrutiny After Patient Death
WEDNESDAY, March 19, 2025 -- A patient has died while receiving Elevidys, a gene therapy for Duchenne muscular dystrophy, marking the first known death linked to the treatment.
The company behind the drug, Sarepta Therapeutics, said that the patient suffered acute liver injury, a known side effect, The Associated Press reported. However, the "severity" of this case had not been seen before, the company noted. Elevidys has been used in more than 800 patients, the company stated.
Sarepta did not release details about the patient but said a recent infection may have played a role in the liver injury. The therapy has been used in more than 800 patients, the company said.
The company plans to update the prescribing information for Elevidys to reflect this case.
Shares of Sarepta, based in Cambridge, Massachusetts, dropped more than 27% on Tuesday, closing at about $73 per share.
Elevidys, which costs $3.2 million for a one-time infusion, was the first gene therapy approved in the U.S. for Duchenne muscular dystrophy, a rare condition that causes muscle weakness, mobility loss and early death in males.
The FDA first granted the drug expedited approval in 2023, despite some scientists questioning its effectiveness.
In 2024, the agency expanded full approval to include patients 4 and older, regardless of mobility status.
The therapy works by using a disabled virus to insert a gene that helps the body produce dystrophin, a protein crucial for muscle function. Sarepta said more than 800 patients have received Elevidys so far, The Associated Press reported.
Sarepta has secured FDA accelerated approval for three other Duchenne drugs since 2016. But none have yet been confirmed to be effective and further studies are still ongoing.
Sources
- The Associated Press, March 18, 2025
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Read this next
Mouse Study Offers Cautionary Tale About The Keto Diet
SUNDAY, Sept. 28, 2025 — It sounds counterintuitive: Eat more fat and lose more weight. But it’s the underpinning of a keto diet — a controversial eating...
Three Health Conditions Raise Death Risk For Fatty Liver Disease
FRIDAY, Sept. 19, 2025 — People with fatty liver disease are more likely to die early if they have one of three additional health problems, a new study says. High blood...
Hall-of-Famer Dan Marino Shares 20-Year Struggle With Liver Disease
THURSDAY, Sept. 18, 2025 — Football legend Dan Marino has disclosed that he has been living with a serious liver condition for nearly 20 years. The former Miami...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.